Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy

Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy

US Patent 11318164 · Granted May 3, 2022

Estimated economic value: $16,599,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Targeted replacement of endogenous T cell receptors2025
Conjugates of an IL-2 moiety and a polymer2025
Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist2025
Methods and compositions for treating melanoma2025
Targeted replacement of endogenous T cell receptors2023
Targeted replacement of endogenous T cell receptors2022
Methods for stratifying non-responders to therapies that block PD1/PDL1 axis2022
Targeted replacement of endogenous T cell receptors2021
Targeted replacement of endogenous T cell receptors2021
Conjugates of an IL-2 moiety and a polymer2021
Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti2020
Detection and treatment of anti-PD-1 therapy resistant metastatic melanomas2020